<DOC>
	<DOCNO>NCT00605150</DOCNO>
	<brief_summary>MDS Nordion 's TheraSphere , Yttrium-90 glass microspheres approve Humanitarian device authorize federal ( USA ) law use radiation treatment neoadjuvant surgery transplantation patient unresectable hepatocellular carcinoma ( HCC ) placement appropriately position hepatic arterial catheter . Outcomes treatment protocol monitor report Carolinas HealthCare System Institutional Review Board .</brief_summary>
	<brief_title>HDE Use Protocol TheraSphere Treatment Unresectable HCC</brief_title>
	<detailed_description>The objective study provide supervised access treatment TheraSphere eligible patient Hepatocellular Carcinoma liver surgical resection candidate evaluate patient experience , toxicity overall survival associate TheraSphere treatment . This observational treatment use protocol provide IRB oversight documentation clinical experience patient undergoing treatment liver carcinoma use TheraSphere . Participation involve investigational research procedure . Patients follow treatment-related adverse experience monitor accordance institutional practice . Approximately 60 patient enrol treatment protocol number may expand follow completion first cohort . The total number patient treat determine base clinical experience patient outcomes . There control subject treatment protocol . The duration protocol depend patient experience treatment . An initial one year approval seek time . Patient experience evaluate continuously clinicians find treatment provide benefit patient , renewal approval seek first 12 month .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Confirmed diagnosis intrahepatic carcinoma . The histopathology confirmation criterion may waive patient radiographically identifiable liver mass , know laboratory clinical risk factor cancer elevate tumor marker AFP ( clinical diagnosis ) . The cancer must unresectable . ECOG Performance Status Score 02 Age great equal 18 Able comprehend provide write informed consent accordance institutional federal guideline . Any pretreatment lab finding within 15 day treatment demonstrating : absolute granulocyte count less equal 1,500/ul , platelet count less equal 45,000/ul , serum creatinine great equal 3.0 mg/dl , serum bilirubin great equal 4.0 mg/dl Any follow contraindication angiography selective visceral catheterization : history severe allergy intolerance contrast medium , narcotic , sedative , atropine ; bleed diathesis , correctable usual form therapy ; severe peripheral vascular disease would preclude catheterization Portal hypertension portal venous shunt away liver Evidence potential delivery great 16.5 mCi ( 30 Gy absorb dose ) radiation lung either 1 ) first TheraSphere administration 2 ) cumulative delivery radiation lung &gt; 30Gy multiple treatment . Evidence detectable Tc99m MAA flow stomach duodenum , application establish angiographic technique stop flow . Significant extrahepatic disease represent imminent lifethreatening outcome Severe liver dysfunction pulmonary insufficiency Active uncontrolled infection Significant underlying medical psychiatric illness . Pregnant woman may participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Unresectable HCC</keyword>
</DOC>